Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Daily Values
Growth Metrics
Income Statement
Others
Ratios

China SXT Pharmaceuticals (SXTC) Other Non-Current Assets (2021 - 2024)

China SXT Pharmaceuticals (SXTC) has 4 years of Other Non-Current Assets data on record, last reported at $8.3 million in Q1 2024.

  • For Q1 2024, Other Non-Current Assets fell 4.88% year-over-year to $8.3 million; the TTM value through Mar 2024 reached $8.3 million, down 4.88%, while the annual FY2024 figure was $8.3 million, 4.88% down from the prior year.
  • Other Non-Current Assets reached $8.3 million in Q1 2024 per SXTC's latest filing, down from $8.7 million in the prior quarter.
  • Across five years, Other Non-Current Assets topped out at $9.5 million in Q1 2022 and bottomed at $8.3 million in Q1 2024.
  • Average Other Non-Current Assets over 4 years is $8.9 million, with a median of $8.9 million recorded in 2021.
  • Peak YoY movement for Other Non-Current Assets: rose 3.35% in 2022, then fell 7.69% in 2023.
  • A 4-year view of Other Non-Current Assets shows it stood at $9.2 million in 2021, then rose by 3.35% to $9.5 million in 2022, then dropped by 7.69% to $8.7 million in 2023, then fell by 4.88% to $8.3 million in 2024.
  • Per Business Quant database, its latest 3 readings for Other Non-Current Assets were $8.3 million in Q1 2024, $8.7 million in Q1 2023, and $9.5 million in Q1 2022.